A newly designed microarray core, including a newly hired manager, and faculty leader, has been established since November, 2004, with the purpose of offering full service, affordable, microarray services to Cancer Center members. The Core operates in conjunction with support from the Department of Medicine and has close links to the School of Medicine Affymetrix core and is seamlessly linked to the new Bioinformatics Core in the Cancer Center. Using the long-oligo Agilent platform, the Center Core offers full 40K human, and mouse, 23 K rat, and 10K yeast gene expression coverage. The facility also has the capacity to utilize custom gene expression arrays from Agilent and has facilities for printing custom human, mouse, and canine cDNA arrays as well. Most recently, the Core offers an Agilent 44K gene transcript oligo based CGH coverage for comprehensive structural analysis of all human chromosomes. The full service offered to investigators includes optional RNA and DNA extraction, QC of RNA and DNA samples, hybridization, scanning and provision of an annotated gene list, or detailed chromosome maps for CGH data, with Agilent software analysis of statistical significance of gene expression changes, etc. In conjunction with the Bioinformatics Core, users are offered instruction for full data analyses, with consultation and collaborative links to the Bioinformatics Core for the most sophisticated needs. Powerful Bioconductor software has been adapted, by the Informatics Core, for encompassing Agilent data. Regular microarray seminars, arranged by the Bioinformatics Core, and presentations by Agilent and other array offering companies, arranged by the Microarray Core, are made available to all users and Center members and also to the School of Medicine community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117671
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$195,097
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Huang, Peng; Park, Seyoun; Yan, Rongkai et al. (2018) Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. Radiology 286:286-295
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Ye, I Chae; Fertig, Elana J; DiGiacomo, Josh W et al. (2018) Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes. Mol Cancer Res 16:1889-1901
Kaur, Harsimar B; Guedes, Liana B; Lu, Jiayun et al. (2018) Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 31:1539-1552
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74

Showing the most recent 10 out of 2393 publications